Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Next Previous
Trial Profile

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BDC-3042 (Primary) ; Cemiplimab (Primary)
  • Indications Colon cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bolt Biotherapeutics

Most Recent Events

  • 12 May 2025 According to Bolt Biotherapeutics media release, data from this study presented at the AACR Annual Meeting 2025 in April 2025.
  • 08 May 2025 According to Bolt Biotherapeutics media release, company will discuss result from this study at a company hosted key opinion leader (KOL) conference call and webcast on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET.
  • 30 Apr 2025 Results (n=17) presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top